Sign in4 stories
The company's August 21 amendment clarifies that director Michael Grissinger joined the Compensation Committee on August 18, 2026, with added annual pay for the role.
SEC filing
Lipocine plans an FDA guidance meeting in the third quarter of 2026 and has started a new placebo-controlled trial for LPCN 1154 after a post hoc analysis flagged one site's data.
SEC filing
The biopharmaceutical company expanded its board to five members, adding a former Johnson & Johnson licensing and M&A executive effective August 3, 2026.
SEC filing